Asad Haider
Stock Analyst at Goldman Sachs
(2.31)
# 2,437
Out of 4,829 analysts
5
Total ratings
100%
Success rate
5.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $154.22 | +11.53% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $734.57 | +20.89% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $184.60 | +5.09% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $46.45 | +18.41% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $22.28 | +12.21% | 1 | Apr 8, 2025 |
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $154.22
Upside: +11.53%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $734.57
Upside: +20.89%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $184.60
Upside: +5.09%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $46.45
Upside: +18.41%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $22.28
Upside: +12.21%